RxDoctor Payments Data

Kate Catudal

Nurse Practitioner · Pawtucket, RINPI 1780340554

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 24.6% of the total. Among nurse practitioner clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,759in general payments, 2019–2025

Across 94 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$433
  • AstraZeneca$302
  • AbbVie$188
  • Pfizer$112
  • Lilly USA, LLC$105
  • Exact Sciences$88
  • plus $532 from 16 others

What the payments were for

  • Food & beverage$1,759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,759 in reported general payments places this provider in the 90th percentile of 396 nurse practitioner providers in Rhode Island.

See all nurse practitioner providers in Rhode Island

Medicare billing

Part B allowed, 2024
$24,217
Medicare patients
73
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$38,429
OzempicSemaglutide39$37,527
JardianceEmpagliflozin24$26,025
EliquisApixaban13$15,180
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,737
Albuterol Sulfate HfaAlbuterol Sulfate70$1,994
Omeprazole119$1,442
Atorvastatin Calcium137$1,220
Lisinopril102$1,110
Duloxetine Hcl37$1,104
Levothyroxine Sodium102$1,051
Fluticasone Propionate51$1,013
Metformin Hcl ErMetformin Hcl106$868
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$794
Gabapentin45$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$433$38,42960 claims
Novo NordiskOzempic$55$37,52739 claims
Boehringer IngelheimJardiance$79$26,02524 claims
PfizerEliquis$112$15,18013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 396 nurse practitioner providers in Rhode Island.

Other nurse practitioner in Pawtucket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →